Keum-Ju Choi; Soo Kyun Jung; Kyung Chan Kim; Eun Jin Kim

doi:10.4266/acc.2022.00941.e1

Articles

Page Path: HOME > Acute Crit Care > Volume 38(2); 2023 > Article

Corrigendum Infection Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”: Keum-Ju Choi, Soo Kyun Jung, Kyung Chan Kim, Eun Jin Kim; Acute and Critical Care 2023;38(2):249-249.
DOI: https://doi.org/10.4266/acc.2022.00941.e1
Published online: May 25, 2023

Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea

Corresponding author Eun Jin Kim Department of Internal Medicine, Daegu Catholic University Medical Center, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu 42472, Korea Tel: +82-53-650-4274 Fax: +82-53-650-4942 Email: ejkim77@cu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,379 Views
57 Download

prev next

Full Article

Download PDF

This corrects the article "Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study" on page 57.

Acute and Critical Care 2023;38:57-67

https://doi.org/10.4266/acc.2022.00941

In the article entitled “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study,” some data of Table 3 was incorrectly presented. The correct Table 3 is as follows.

Table 3.

Treatment and prognosis in critical or severe COVID-19 cases with control and pulse steroid groups

Variable	Control steroid (n=14)	Pulse steroid (n=30)	Total (n=44)	P-value
High flow nasal cannula oxygen	14 (100)	29 (96.7)	43 (97.7)	0.490
Mechanical ventilation	4 (28.6)	6 (20.0)	10 (22.7)	0.527
Duration of mechanical ventilation (day)	18 (11–33)	8 (4–10)	10 (6–8)	0.063
Other treatment^a)	1 (7.1)	3 (10.0)	4 (9.1)	0.759
Prone position^b)	7 (50.0)	21 (70.0)	28 (63.6)	0.199
In-hospital mortality	6 (42.9)	7 (23.3)	13 (29.5)	0.186
In-hospital mortality among moderate and mild ARDS groups	4 (44.4)	2 (13.3)	6 (25.0)	0.088
In-hospital mortality among severe ARDS group	2 (40.0)	5 (33.3)	7 (35.0)	0.933
28-Day mortality	5 (35.7)	7 (23.3)	12 (27.3)	0.390
Cause of death				0.255
Respiratory failure	4 (28.6)	5 (16.7)	9 (20.5)
Hepatic failure	2 (14.3)	0	2 (4.5)
Arrhythmia	0	1 (3.3)	1 (2.3)
Renal failure	0	1 (3.3)	1 (2.3)
Length of hospital stay (day)	14 (12–24)	11 (9–16)	11 (8–17)	0.039^d)
Complication after steroid use	1 (7.1)	3 (9.9)	4 (9.0)	0.295
Uncontrolled hyperglycemia	0	2 (6.7)	2 (4.8)
Others^c)	1 (7.1)	1 (3.3)	2 (4.8)

Values are presented as number (%) or median (interquartile range).

COVID-19: coronavirus disease 2019; ARDS: acute respiratory distress syndrome.

^a)Other treatment includes renal replacement therapy or extracorporeal membrane oxygenation;

^b)Awake prone positioning;

^c)One gastrointestinal bleeding case in control steroid group and 1 candidemia case in pulse steroid group;

^d)Mann-Whitney U-test for comparisons between the control and pulse steroid groups.

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”

Acute Crit Care. 2023;38(2):249-249. Published online May 25, 2023

DOI: https://doi.org/10.4266/acc.2022.00941.e1

XML Download

Related articles

Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study

Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”

Variable	Control steroid (n=14)	Pulse steroid (n=30)	Total (n=44)	P-value
High flow nasal cannula oxygen	14 (100)	29 (96.7)	43 (97.7)	0.490
Mechanical ventilation	4 (28.6)	6 (20.0)	10 (22.7)	0.527
Duration of mechanical ventilation (day)	18 (11–33)	8 (4–10)	10 (6–8)	0.063
Other treatment^a)	1 (7.1)	3 (10.0)	4 (9.1)	0.759
Prone position^b)	7 (50.0)	21 (70.0)	28 (63.6)	0.199
In-hospital mortality	6 (42.9)	7 (23.3)	13 (29.5)	0.186
In-hospital mortality among moderate and mild ARDS groups	4 (44.4)	2 (13.3)	6 (25.0)	0.088
In-hospital mortality among severe ARDS group	2 (40.0)	5 (33.3)	7 (35.0)	0.933
28-Day mortality	5 (35.7)	7 (23.3)	12 (27.3)	0.390
Cause of death				0.255
Respiratory failure	4 (28.6)	5 (16.7)	9 (20.5)
Hepatic failure	2 (14.3)	0	2 (4.5)
Arrhythmia	0	1 (3.3)	1 (2.3)
Renal failure	0	1 (3.3)	1 (2.3)
Length of hospital stay (day)	14 (12–24)	11 (9–16)	11 (8–17)	0.039^d)
Complication after steroid use	1 (7.1)	3 (9.9)	4 (9.0)	0.295
Uncontrolled hyperglycemia	0	2 (6.7)	2 (4.8)
Others^c)	1 (7.1)	1 (3.3)	2 (4.8)

Table 3. Treatment and prognosis in critical or severe COVID-19 cases with control and pulse steroid groups

Values are presented as number (%) or median (interquartile range).

COVID-19: coronavirus disease 2019; ARDS: acute respiratory distress syndrome.

Other treatment includes renal replacement therapy or extracorporeal membrane oxygenation;

Awake prone positioning;

One gastrointestinal bleeding case in control steroid group and 1 candidemia case in pulse steroid group;

Mann-Whitney U-test for comparisons between the control and pulse steroid groups.